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Impact of Aortic Regurgitation After
Transcatheter Aortic Valve Implantation
Results From the REVIVAL Trial
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Miguel Llano, MD,* Ronen Durst, MD,* Anil A. Reddy, MD,* William W. O’Neill, MD,†
Michael H. Picard, MD*
Boston, Massachusetts; and Miami, Florida
O B J E C T I V E S Understanding the severity of aortic regurgitation (AR) after transcatheter aortic
valve implantation, its impact on left ventricular (LV) structure and function, and the structural factors
associated with worsening AR could lead to improvements in patient selection, implantation technique,
and valve design.
B A C KG ROUND Initial studies in patients at high risk of surgical aortic valve replacement have
reported both central valvular and paravalvular AR after transcatheter aortic valve implantation.
METHOD S Transthoracic echocardiograms were quantiﬁed from 95 patients in the REVIVAL
(TRanscatheter EndoVascular Implantation of VALves) trial. Transthoracic echocardiograms were ob-
tained before implantation of the Edwards-Sapien valve (Edwards Lifesciences, Irvine, California) and
thereafter at selected intervals. Measurements included LV internal diameters and volumes, ejection
fraction, aortic valve area, and the degree of aortic regurgitation. Measures of degree of native leaﬂet
mobility, thickness, and calciﬁcation, as well as left ventricular outﬂow tract, aortic annulus, and aortic
root diameters were also made.
R E S U L T S Eighty-four patients remained after 11 were excluded; 26 (29.8%) died over a period of 3
years. At 24 h post-implantation, 75% had some degree of AR, mostly paravalvular. By 1 year, the mean
AR grade increased slightly, but not signiﬁcantly (1.1 0.8 to 1.3 0.9), and all measures of LV structure
and function improved (LV ejection fraction, 50.7  16.1% to 59.4  14.0%). Native aortic leaﬂet
calciﬁcation and annulus diameter correlated signiﬁcantly with the severity of AR at 1 year (p  0.05).
CONC L U S I O N S AR after transcatheter aortic valve implantation is frequent but is rarely more than
mild. Although AR progresses, it is not associated with a harmful impact on LV structure and function
over the ﬁrst year. Native valve calciﬁcation and aortic annulus diameter inﬂuence the degree of AR at
6 months. (J Am Coll Cardiol Img 2012;5:469–77) © 2012 by the American College of Cardiology
Foundation
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470ortic stenosis (AS) is the most frequent heart
valve disease in Western countries, where its
prevalence steadily increases with age (1).
Once symptoms develop, the average
survival of patients with AS is reduced to 5 years
(2–6). Successful aortic valve replacement results in
a good long-term prognosis (7,8), but unfortu-
nately, 30% of patients with severe AS are re-
jected for cardiac surgery due to excessive surgical
risk (1).
The REVIVAL (TRanscatheter EndoVascular
Implantation of VALves) trial studied the safety
and efficacy of the Edwards-Sapien bioprosthetic
valve (Edwards Lifesciences, Irvine, California) and
its transfemoral and transapical implantation tech-
niques in patients with critical AS at high surgical
risk (9). Most studies examining the efficacy of
transcatheter aortic valve implantation
(TAVI) (10–15) have reported an inci-
dence and degree of aortic regurgitation
(AR) (central or paravalvular) after valve
implantation. However, the structural and
functional sequelae of such regurgitation
are infrequently reported.
Through serial transthoracic echocardio-
grams, we sought to investigate the inci-
dence, location, and severity of AR that
develops after TAVI and its impact on left
ventricular (LV) structure and function. As
well, we sought to identify anatomic or
pathological factors associated with more
severe AR after valve replacement.
M E T H O D S
Patient selection. The REVIVAL trial is a
rospective, multicenter, safety and feasibility study
f percutaneous aortic valve implantation (9). Pa-
ients were recruited from medical centers in the
nited States and included those with severe symp-
omatic AS, defined as a valve area 1.0 cm2 or
0.5 cm2/m2, a mean gradient 40 mm Hg, and
ew York Heart Association functional class III/
V. Inclusion and exclusion criteria have already
een published (9).
Valve implantation. The percutaneous approach was
performed retrograde from the femoral artery or
antegrade by direct implantation via an LV apical
puncture. Valve-in-stent delivery at the site of the
calcified aortic valve was guided using fluoroscopy
and transesophageal echocardiography (TEE).
Aortography and TEE were both used to confirm
device placement and patency of both left and right ucoronary ostia. If excessive paravalvular AR was
noted, then repeat in-valve balloon inflation was
performed, at the discretion of the interventionalist,
to ensure proper apposition of the valve-in-stent
along the aortic annulus.
Echocardiographic parameters. Transthoracic echo-
cardiograms were obtained before implantation of
the Edwards-Sapien valve (baseline), and thereafter
at 24 h, 7 and 30 days, and 3, 6, and 12 months
post-implantation as well as annually thereafter.
These transthoracic echocardiograms were analyzed
at a core echocardiography laboratory blinded to the
details of the patients and procedure. Parameters
from the transthoracic echocardiograms of up to 3
years of follow-up were analyzed. Measurements
included pre- and post-implantation left ventricular
end-diastolic and end-systolic internal diameters,
and left ventricular end-diastolic volume (LVEDV)
and left ventricular end-systolic volume (LVESV)
(using the biplane method of disks). In addition,
pre- and post-implantation aortic valve area (by the
continuity equation), aortic peak velocity, and
Doppler-derived peak and mean gradients across
the aortic valve were measured. Functional mea-
surements included left ventricular ejection fraction
(LVEF), calculated from the LV volume, and
cardiac output, calculated from the product of heart
rate and Doppler-derived stroke volume. Central
AR was quantified by incorporating the vena con-
tracta width and jet height based on the most recent
American College of Cardiology/American Heart
Association valvular guidelines (2). Trace AR was
designated as 1, mild as 2, moderate as 3, and
severe as 4. Paravalvular AR was distinguished
from central, valvular AR (Fig. 1). Paravalvular AR
was graded based on the extent of the circumference
of the stent involved: trace, 5% of valvular cir-
cumference; mild, 10%; moderate, 20%; and
severe, 20% (16). Native valvular structural pa-
rameters evaluated on the baseline transthoracic
echocardiogram included qualitative measures of
degree of leaflet mobility, thickness as well as left
ventricular outflow tract (LVOT), aortic annulus,
and aortic root diameters. Calcification of the native
leaflets was scored based on the degree of reflectivity
(brightness) and percentage of the leaflets involved
(0, 25%; 1, 25% to 50%; 2, 50% to 75%; 3,
75%). Similar data were also collected on succes-
ive transthoracic echocardiograms.
Statistical analysis. Statistical analyses were con-
ucted with SPSS version 13.0 (SPSS Inc., Chicago,
llinois). Measurements are presented as mean  SD,A B B R E V I A T I O N S
A N D A C R O N YM S
AR aortic regurgitation
AS aortic stenosis
LV left ventricular
LVEDV left ventricular
end-diastolic volume
LVESV left ventricular
end-systolic volume
LVOT left ventricular
outflow tract
TAVI transcatheter aortic
valve implantation
TEE transesophageal
echocardiography
TTE transthoracicnless otherwise specified. The Wilcoxon matched-
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471pairs signed-rank test with Bonferroni correction
was used to assess the significance of differences
among continuous variables. An adjusted p value
0.01 was considered statistically significant. Cat-
egorical variables were compared using chi-square
analysis. Correlations between linear measurements
were conducted by univariate linear regression anal-
ysis, whereas correlations between the degree of AR
and certain specific measurements were performed
using Spearman’s correlation. Interobserver vari-
ability was also assessed using Spearman’s
correlation.
R E S U L T S
From 2006 to 2008, the transthoracic echocardio-
grams of 95 patients were available. Eleven patients
were excluded from this analysis because they did
not receive a percutaneous valve. Forty-nine pa-
tients (58.3%) underwent a transfemoral approach,
and the remaining 35 (41.7%) underwent a
transapical approach. Of the 84 patients who re-
ceived a percutaneous valve and formed the final
Figure 1. Color Doppler Echocardiography of a Prosthetic
Aortic Valve
Transthoracic echocardiography (parasternal long-axis view [A];
parasternal short-axis view [B]) demonstrating central, valvular
aortic regurgitation (long arrows) and paravalvular aortic regur-
gitation (short arrow).analysis group, 53 (63.1%) had a 26-mm valve im-planted and 31 patients (36.9%) received a 23-mm
valve. By 6 months, data on 61 patients were available.
In addition, data on 49, 21, and 14 patients were
available at 1, 2, and 3 years, respectively.
AR. At baseline, before valve implantation, the
median degree of native AR was 2.0 (interquartile
range [IQR] [25% to 75%]: 1.0 to 2.0). At 24 h
post-implantation, 75% of patients had some de-
gree of AR detected by transthoracic echocardiog-
raphy (TTE). At 6 months, 89% (54 of 61) of
patients had some degree of AR. At 1 year, that
proportion decreased slightly to 81% (39 of 48) but
remained stable at 2 years (81%; 17 of 21) and 3
years (85%; 11 of 13). The number of patients in
each category of AR at each follow-up interval is
shown in Figure 2. The median AR grade increased
slightly but significantly from 1.0 (IQR: 0.75 to 2.0)
at 24 h to 1.0 (IQR: 1.0 to 2.0) at 6 months
post-implantation (p  0.05 for comparison of
eans). At 1 year (median 1.0; IQR: 1.0 to 2.0) of
ollow-up, the difference in AR grade was no longer
tatistically significant. Similarly, the amount of AR
t 2 (2.0; IQR: 1.0 to 2.0) and 3 (2.0; IQR: 1.0 to
.0) years of follow-up was no different statistically
han that measured 24 h after valve implantation.
At 24 h post-implantation, 39 of 60 patients
65%) with any AR had paravalvular AR, 6 (10%)
ad central AR, and 15 (25%) had evidence of both.
igure 3 highlights the location of AR at each
ollow-up period.
By 1 year, in those patients who started with no
R within 24 h of valve implantation, significantly
ore AR developed (to trace, p  0.001), whereas
hose with trace or mild AR did not change
ignificantly (Fig. 4). Although few in number,
hose patients with moderate AR trended down to
race (p  NS). A similar trend is seen after a
ollow-up of 3 years. Only 1 patient, starting with
oderate AR, survived to 3 years still demonstrat-
ng moderate AR.
Interobserver variability for the grading of AR
as assessed between the 2 readers. The correlation
etween the 2 readers was strong and highly signif-
cant (r  0.816; p  0.0001).
Structural and functional changes. Before percutane-
ous valve implantation, the mean aortic valve area
was 0.6  0.2 cm2, the aortic valve peak velocity
was 4.1  0.7 m/s, and the aortic valve peak and
mean gradients were 70.2  23.3 mm Hg and 43.4 
15.1 mm Hg, respectively. As expected, these pa-
rameters all improved significantly immediately af-
ter valve implantation (p  0.0001). Measurements
wJ A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 4 6 9 – 7 7
Yared et al.
AR After TAVI
472remained similar for up to 3 years post-implantation
(Table 1).
Compared with pre-implantation measurements,
the mean aortic root diameter, LVESD, and
LVEDD did not change significantly up to 3 years.
On the other hand, the LVEDV and LVESV
decreased significantly up to 1 year. Although
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473the latter group, LV volumes decreased significantly
(LVEDV 83.6  43.3 ml vs. 104.3  42.8 ml, p 
0.01; LVESV 38.1  31.6 ml vs. 55.0  37.4 ml,
 0.01), whereas the difference in volumes in the
moderate AR group was not statistically significant
(LVEDV 158.0  58.6 ml vs. 129.7  47.8 ml,
p  NS; LVESV 74.7  61.0 ml vs. 77.3  75.2
ml, p  NS). In addition, both mean LVEDV and
mean LVESV at 1 year were greater in the mod-
erate AR group compared with those with no or
trace AR (p  0.001). However, it must be noted
that the baseline end-diastolic and end-systolic
volumes of those patients with at least moderate AR
at 1 year were much greater than those with trace or
no AR at 1 year.
Survival outcome. Survival data were available up to
3.3 years after valve implantation. Seventeen pa-
tients (19.5%) had died within 6 months of valve
implantation, 21 patients within 1 year, and a total
of 27 patients were dead by 3.3 years. Mean survival
at 3.3 years was not significantly different among
the groups of no, trace, and mild AR (Fig. 5). Only
2 patients had moderate AR at 24 h post-
implantation; 1 died 3 months post-implantation,
and the other died after 3 years.
Predictors of AR. The differences between the diam-
eter of the aortic annulus and the implanted
prosthetic valve were calculated. The implanted
valve was almost always greater than the mea-
sured annulus (median difference of 4.4 mm;
IQR: 3.1 to 6.0 mm). No correlation was
found between these differences and the total
amount of AR at 1 year.
Table 1. Structural and Functional Parameters of the Left Ventr
Percutaneous Valve Replacement
Parameters
Baseline
(n  84)
Within 7 Days
(n  80)
Structural
LVEDD, mm 45.4 6.1 44.0 7.0
LVESD, mm 32.5 8.4 30.4 8.9
LVEDV, ml 105.0 42.8 100.2 44.4*
LVESV, ml 55.6 38.8 48.9 34.9*
Aortic root, mm 31.1 3.4 29.9 4.5
AV peak velocity, m/s 4.1 0.7 2.1 0.4
AVA, cm2 0.6 0.2 1.6 0.4*
AV PG, mm Hg 70.2 23.3 18.6 7.2*
AV MG, mm Hg 43.4 15.1 9.6 3.8*
Functional
Cardiac output, l/min 4.1 1.0 4.8 1.5*
LVEF, % 50.7 16.1 55.6 16.3*
Values are mean  SD unless otherwise indicated. *Statistical signiﬁcance (p 
AV  aortic valve; AVA  aortic valve area; LVEDD  left ventricular end-diastejection fraction; LVESD  left ventricular end-systolic diameter; LVESV  left ventrMeasurements of the severity of AR at 1 year
were split into 2 groups according to implanted
valve size. Of those who received a 23-mm valve
and were alive at 1 year, 12 of 18 (66.7%) had some
degree of AR, most of which was paravalvular (7 of
12). In the 26-mm valve group, 27 of 30 (90.0%)
had some degree of AR, most of which was again
paravalvular (16 of 27). Both 6-month and 1-year
data are presented in Table 2. The size of the
implanted valve did not correlate significantly with
the severity of AR nor did it influence the location
M
ed
ia
n 
De
gr
ee
 o
f A
or
tic
 R
eg
ur
gi
ta
tio
n
Time After Implantation
4
3
2
1
0
24 hours 7 days 30 days 3 months 6 months 1 year 2 ye
Figure 4. Progression of AR After Percutaneous Aortic Valve Im
Linear graph demonstrating progression of each (median) grade of
tion (AR) based on its severity 24 h after valve replacement. 0  no
AR; 2  mild AR; 3  moderate AR.
at Baseline and Follow-Up After
Months
n  61)
1 Year
(n  49)
2 Years
(n  21)
3 Years
(n  14)
.4 7.8 43.7 6.9 45.7 8.4 43.4 9.1
.6 9.4 28.6 8.2 30.9 9.5 28.7 9.6
.6 42.1* 89.5 48.9* 82.2 45.3 84.3 50.3
.7 32.9* 41.0 34.9* 38.9 33.8 40.8 34.9
.8 3.7 31.3 2.9 30.6 3.2 31.3 3.0
.1 0.4 2.1 0.4 2.2 0.4 2.2 0.5
.5 0.4* 1.5 0.4* 1.4 0.3* 1.4 0.3*
.9 7.4* 18.6 7.1* 18.9 6.9* 19.3 8.5*
.6 4.2* 9.6 3.8* 9.7 3.5* 9.9 4.9*
.6 1.2* 4.5 1.2* 4.5 1.2* 4.2 0.9*
.3 13.4* 59.4 14.0* 57.8 12.4* 55.9 11.7*
1) compared with baseline values.
iameter; LVEDV  left ventricular end-diastolic volume; LVEF  left ventricularars 3 years
0+
1+
2+
3+
plantation
aortic regurgita-
AR; 1  traceicle
6
(
44
29
92
43
30
2
1
18
9
4
57
0.0
olic dicular end-systolic volume; MG  mean gradient; PG  peak gradient.
c
A
f
R; 1
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 4 6 9 – 7 7
Yared et al.
AR After TAVI
474of AR at 6 months. More patients with a 23-mm
valve had central mild to moderate AR compared
with those with a 26-mm valve. However, more
patients with a 26-mm valve had a combination
of central and paravalvular, mild to moderate AR.
The method of implantation (transfemoral or
transapical) had no bearing on the degree or
location of AR at 1 year.
Native LVOT, aortic annulus, root and leaflet
dimensions, and pathology were evaluated to eluci-
date whether they determined the severity of AR at
1 year. At baseline, the mean native LVOT diam-
eter was 19.7  1.7 mm. As expected, the amount
of leaflet calcification, mobility, and thickening was
significantly less in the bioprosthetic valve at 1 year
compared with the baseline native valve. The aortic
annulus diameter decreased significantly at 1 year
(18.2  2.1 mm vs. 20.5  2.6 mm). Baseline
LVOT and aortic root dimensions did not correlate
with the severity of AR both at 6 months and 1
year. The amount of native leaflet calcification
(mean score 2.4  0.6) correlated significantly with
the severity of AR at 6 months (r 0.25; p 0.05)
as did the pre-implantation aortic annulus diame-
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D I S C U S S I O N
In this study, we aimed to review the incidence of
any type of AR after TAVI with the Edwards-
Sapien valve and examine its effects on LV structure
and function. This was accomplished by evaluating
the trial-mandated transthoracic echocardiograms
at a core laboratory. In addition, we sought specific
anatomic features of the native valve and aortic root
that would be associated with more severe AR.
We found that AR after deployment of the
Edwards-Sapien valve occurs frequently; 75% of
patients had some form of AR, detected by TTE,
within 24 h of implantation. However, typically, the
AR was of trace or mild severity. Trace central AR
is a physiological finding for this bioprosthesis.
Detection of paravalvular AR was more common
than central AR regardless of the method of im-
plantation or the size of the valve. Although the
fully expanded valve-in-stent is round, the aortic
ow-Up
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475a perfect circle and the presence of paravalvular AR
immediately after implantation would not be unex-
pected. AR progressed somewhat over the course of
1 year, although, in most cases, it remained mild or
less. Although this increase in severity was statisti-
cally significant, it was not associated with signs of
clinical significance such as increased LV volumes
or decreased LVEF.
Interestingly, patients with no AR immediately
post-implantation progressed, whereas those with
trace or mild AR did not progress. It is not entirely
clear why those with no AR progress; however, this
may be related to remodeling of the LVOT, aortic
annulus, and sinuses of Valsalva after implantation
of the valve that does not allow complete apposition
of the valve-in-stent to the surrounding annulus.
On the other hand, those with moderate AR
trended toward trace AR at 6 months, which then
increased to moderate at 3 years, although this
comparison lacked statistical significance, mostly
Table 2. Breakdown of Location of AR According to
Implanted Valve Size
Severity of AR at
6 Months
Implanted Valve Size, mm
p Value23 (n  24) 26 (n  37)
Total
0/1 17 (70.8) 25 (67.6) NS
2/3 7 (29.2) 12 (32.4) NS
Paravalvular
0/1 10 (41.7) 15 (40.5) NS
2/3 2 (8.3) 4 (10.8) NS
Central
0/1 2 (8.3) 4 (10.8) NS
2/3 3 (12.5) 0 (0.0) 0.007
Both
0/1 1 (4.2) 1 (2.7) NS
2/3 2 (8.3) 8 (21.6) 0.02
Severity of AR at
1 Year (n  18) (n  30)
Total
0/1 14 (77.8) 16 (53.3) NS
2/3 4 (22.2) 14 (46.7) NS
Paravalvular
0/1 6 (33.3) 11 (36.7) NS
2/3/4 1 (5.5) 5 (16.7) NS
Central
0/1 0 (0.0) 1 (3.3) NS
2/3/4 1 (5.5) 5 (16.7) NS
Both
0/1 1 (5.5) 1 (3.3) NS
2/3/4 1 (5.5) 6 (20.0) NS
AR  aortic regurgitation.due to the small number of patients. As mentionedpreviously, very few patients are left with moderate
or more AR immediately after valve implantation
because redilation of the valve is often performed if
this amount of AR is noted. Redilation of a
valve-in-stent is not without consequence because
this technique may damage the cusps, resulting in
worsened AR. However, this type of injury to the
cusps was not noted in any patient in our study.
The degree of AR appears to stabilize over 3
years. Additionally, it is not associated with a
harmful impact on LV structure and function. The
improved structural and functional changes most
likely reflect the effect of the relief of aortic stenosis.
It is encouraging however, that, overall, the amount
of AR did not adversely affect LV structure or
function. The REVIVAL trial mandated that
TAVI be used in an elderly cohort of patients with
calcific AS who were at very high surgical risk.
Therefore, most interest is in a shorter term natural
history. The most important finding is that even
though some severity of AR is introduced into the
already pressure-overloaded, hypertrophied left
ventricle of long-standing AS, it is well tolerated.
When evaluated separately, LV volumes in those
with moderate AR at 1 year were not significantly
different from those at baseline compared with the
significant reductions in volumes seen in those with
no or trace AR. Unfortunately, given the small
number of patients, it is difficult to draw definitive
conclusions. However, the lack of significant
change in LV volumes may signal an important
effect on LV structure over the long term. Although
we present data up to 3 years of follow-up, a larger
number of patients in the moderate AR group are
necessary for a more accurate evaluation.
The diameter of the aortic annulus and the
degree of native valve calcification on TTE before
valve replacement predicted the degree of AR 12
months after replacement. A larger aortic annulus
led to more central AR. This may be explained by
the fact that a larger annulus, in addition to requir-
ing the largest valve-in-stent available, would re-
quire the most amount of post-dilation and thus
potentially result in mild, central leaflet separation.
On the other hand, more heavily calcified valves led
to relatively more paravalvular AR, which may
reflect the incomplete apposition of the stent valve
against a markedly calcified boundary, thereby cre-
ating potential “channels” of paravalvular AR.
The size of the implanted valve had no bearing
on the type or severity of AR that developed over
the period of observation. A larger valve is usually
chosen to minimize the resultant paravalvular leak
t
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476or risk of migration of an undersized valve. It is
possible that our TTE measurements underesti-
mate the annular size due to beam spread artifact
from the highly reflective annular calcification. For
this reason, some centers are now favoring the use
of computed tomography for aortic annulus mea-
surement (17). Furthermore, the actual diameter of
the valve did not correlate with the severity of AR
at 6 and 12 months. In aggregate, it seems that in
most instances, the correct valve size was chosen,
and this subsequently had no bearing on the devel-
opment or worsening of AR. This finding is in
contrast with a recent study suggesting that the lack
of congruence between prosthesis and annulus size
measured by TTE, as assessed by the ratio of one to
he other, is a strong determinant of paravalvular AR
18). In addition to annulus diameter, the geometry
nd shape of the annulus, the angle between the axis
f the LVOT and that of the ascending aorta, and the
mount and location of native leaflet calcification have
ll been examined and should serve as important
onsiderations (19–21) in the selection of the most
ppropriate valve.
Cribier et al. (11,22) reported the results of the
initial 36 percutaneous transcatheter aortic valve
replacements performed as part of 2 single-center
registries. In both series, AR was paravalvular in all
cases and at least moderate in severity in 17 of 27
patients (63%). The amount of paravalvular leak
was unchanged in most patients at 4-week follow-
up. It is important to note that Cribier et al. (11,22)
used 23-mm valves exclusively because this was the
only size available for implantation at that time.
This valve size may have been undersized in a
number of patients and perhaps contributed to the
high prevalence of paravalvular AR.
The initial observations by the groups of Cribier
et al. (10,11) and Webb et al. (12,13) led to
technical refinements including the introduction of
a 26-mm valve to help reduce paravalvular regurgi-
tation. Using these refinements, Webb et al. (13)
reported, in their series of 50 high-risk patients that
central valvular AR was no more than mild and that
patients had some degree of paravalvular AR. The 3
patients with moderate paravalvular AR remained
stable at 12-month follow-up.
More recently, clinical results from the PARTNER
(Placement of Aortic Transcatheter Valves) trial
demonstrate mostly mild AR at 30 days and 1 year
post-implantation of Edwards-Sapien valves (al-
though moderate or severe AR was present in
11.8% and 10.5% at 30 days and 1 year, respec-tively) (15). In that cohort, the amount of AR
remained stable during the 1-year follow-up period.
Study limitations. In our study, the structural and
functional impact of up to mild AR on the LV is
limited to the duration of follow-up. In addition,
the number of patients with moderate AR after
valve implantation was too small to include in
robust statistical analyses.
The REVIVAL trial used TTE to assess valve
dynamics and area, with a limited assessment of
AR. The evaluation of AR post-TAVI can be very
challenging, especially when it involves more than
one part of the circumference around the valved
stent. Serious attempts were made to evaluate the
degree of AR in the most quantitative manner.
However, a fully quantitative analysis of AR in this
study is limited.
Understanding the position of the device or its
orientation in relation to surrounding structures is
difficult by 2-dimensional TTE unless one relates it
to the transducer position. This type of assessment
should ideally be performed by TEE during valve
implantation. Reassessment of the precise valve
position during follow-up may be better performed
using 3-dimensional TTE, TEE, or other nonin-
vasive imaging modalities. This was not part of the
study protocol and may be the objective of future
work in this area.
C O N C L U S I O N S
In summary, central and paravalvular AR is
common after percutaneous aortic valve replace-
ment at 1 year follow-up, but the amount of
regurgitation is small and does not result in
harmful effects on LV structure and function.
Paravalvular AR does seem to progress over the
course of 12 months, but remains no more than
mild in the overwhelming majority of cases.
Native aortic leaflet calcification and aortic annu-
lus diameter influence the severity of paravalvular
and central AR, respectively. This study provides
a motivation for larger imaging trials with longer
follow-up to quantify and evaluate the clinical
significance of both forms of residual AR.
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